TY  - JOUR
AU  - Paz-Ares, Luis G
AU  - Ramalingam, Suresh S
AU  - Ciuleanu, Tudor-Eliade
AU  - Lee, Jong-Seok
AU  - Urban, Laszlo
AU  - Caro, Reyes Bernabe
AU  - Park, Keunchil
AU  - Sakai, Hiroshi
AU  - Ohe, Yuichiro
AU  - Nishio, Makoto
AU  - Audigier-Valette, Clarisse
AU  - Burgers, Jacobus A
AU  - Pluzanski, Adam
AU  - Sangha, Randeep
AU  - Gallardo, Carlos
AU  - Takeda, Masayuki
AU  - Linardou, Helena
AU  - Lupinacci, Lorena
AU  - Lee, Ki Hyeong
AU  - Caserta, Claudia
AU  - Provencio, Mariano
AU  - Carcereny, Enric
AU  - Otterson, Gregory A
AU  - Schenker, Michael
AU  - Zurawski, Bogdan
AU  - Alexandru, Aurelia
AU  - Vergnenegre, Alain
AU  - Raimbourg, Judith
AU  - Feeney, Kynan
AU  - Kim, Sang-We
AU  - Borghaei, Hossein
AU  - O'Byrne, Kenneth John
AU  - Hellmann, Matthew D
AU  - Memaj, Arteid
AU  - Nathan, Faith Ellen
AU  - Bushong, Judith
AU  - Tran, Phuong
AU  - Brahmer, Julie R
AU  - Reck, Martin
PY  - 2021
DO  - 10.1016/j.jtho.2021.09.010
UR  - http://hdl.handle.net/10668/22342
T2  - Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
AB  - In CheckMate 227, nivolumab plus ipilimumab prolonged overall survival (OS) versus chemotherapy in patients with tumor programmed death-ligand 1 (PD-L1) greater than or equal to 1% (primary end point) or less than 1% (prespecified descriptive...
LA  - en
KW  - CTLA-4
KW  - First-line
KW  - Immunotherapy
KW  - Metastatic non–small cell lung cancer
KW  - PD-1 checkpoint inhibitor
KW  - Adult
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Humans
KW  - Ipilimumab
KW  - Lung Neoplasms
KW  - Neoplasm Recurrence, Local
KW  - Nivolumab
TI  - First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial.
TY  - research article
VL  - 17
ER  -